Tamjeed Arshad, MD
Clinical Cardiac Electrophysiology · Montgomery, ALNPI 1568492544
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,000 of the $36,661 with a category attached, or 65.5%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 69.5% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2021 at $8,234 and has fallen 84.7% since, to $1,260 in 2025.
Across 442 payments — averaging $82.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$25K
- Abbott$3K
- Medtronic$2K
- Pfizer$999
- Novartis$635
- Johnson & Johnson$577
- plus $4K from 36 others
Across 1 payment — averaging $857.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$858
What the payments were for
- Consulting fees$1,9505%
- Speaking & faculty fees$24,00065%
- Travel & lodging$3411%
- Food & beverage$9,93227%
- Education$4381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,661 in reported general payments places this provider in the 65th percentile of 42 clinical cardiac electrophysiology providers in Alabama.
See all clinical cardiac electrophysiology providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 52 | $1,332,248 |
| EliquisApixaban | 385 | $355,892 |
| EntrestoSacubitril/Valsartan | 175 | $185,818 |
| FarxigaDapagliflozin Propanediol | 117 | $108,430 |
| JardianceEmpagliflozin | 77 | $84,121 |
| XareltoRivaroxaban | 65 | $70,970 |
| MultaqDronedarone Hcl | 50 | $58,989 |
| Repatha SureclickEvolocumab | 37 | $27,090 |
| BrilintaTicagrelor | 20 | $16,182 |
| VascepaIcosapent Ethyl | 12 | $12,082 |
| Metoprolol Succinate | 338 | $4,936 |
| Ranolazine ErRanolazine | 19 | $3,166 |
| Atorvastatin Calcium | 188 | $3,135 |
| Amiodarone Hcl | 59 | $1,858 |
| Carvedilol | 180 | $1,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $999 | $1,688,139437 claims |
| NovartisEntresto | $635 | $185,818175 claims |
| AstraZenecaFarxiga, Brilinta | $204 | $124,612137 claims |
| Boehringer IngelheimJardiance | $145 | $84,12177 claims |
| Johnson & JohnsonXarelto | $577 | $70,97065 claims |
| Sanofi-aventis U.S. LLCMultaq | $150 | $58,98950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 42 clinical cardiac electrophysiology providers in Alabama.
Other clinical cardiac electrophysiology in Montgomery
- Wynne CrawfordMontgomery$12K
- Hugh McElderryBirmingham$725K
- Anil RajendraBirmingham$495K
- Gustavo MoralesBirmingham$171K
- William MaddoxBirmingham$159K
- Francis BennBirmingham$95K
- Terence DunnBirmingham$73K
- Thomas TurnageMobile$71K
- Ernest QuinMobile$65K
- Byron ColleyBirmingham$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.